Free Trial

Alvotech Q4 2024 Earnings Report

Alvotech logo
$9.27 +0.08 (+0.87%)
As of 04/3/2025 04:00 PM Eastern

Alvotech EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.74
Beat/Miss
Beat by +$0.50
One Year Ago EPS
N/A

Alvotech Revenue Results

Actual Revenue
$153.34 million
Expected Revenue
$97.99 million
Beat/Miss
Beat by +$55.35 million
YoY Revenue Growth
N/A

Alvotech Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Alvotech Earnings Headlines

Alvotech (ALVO) Gets a Buy from Northland Securities
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Alvotech appoints Balaji Prasad as chief strategy officer
This Is a Test From GlobeNewswire
See More Alvotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alvotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alvotech and other key companies, straight to your email.

About Alvotech

Alvotech (NASDAQ:ALVO), through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

View Alvotech Profile

More Earnings Resources from MarketBeat